RxDoctor Payments Data

Kathryn Shunnarah

Nurse Practitioner · Rockledge, FLNPI 1699837104

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $17,471 of the $22,233 with a category attached, or 78.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,233in general payments, 2019–2025

Across 920 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • Merck$1K
  • Amgen$724
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$17,47179%
  • Education$1,1485%
  • Other$3,61416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis119$4,849
Johnson & Johnson84$1,825
AstraZeneca62$1,534
Pfizer75$1,379
Merck62$1,340
Amgen26$724
Lilly USA, LLC28$695
Incyte Corporation33$683
Astellas Pharma US Inc36$676
Seagen Inc.26$666
Sanofi25$531
Takeda Pharmaceuticals U.S.A., Inc.25$521
Daiichi Sankyo Inc.18$457
Bristol Myers Squibb22$453
Bayer20$368
Eisai Inc.17$353
Regeneron Healthcare Solutions, Inc.13$311
AbbVie14$311
E.r. Squibb & Sons, L.L.C.15$269
Genentech USA, Inc.14$262
Karyopharm Therapeutics Inc.12$241
Puma Biotechnology, Inc.11$206
Beigene USA, Inc.10$200
Ipsen Biopharmaceuticals, Inc9$178
Array Biopharma Inc8$173
GSK7$161
Agios Pharmaceuticals, Inc.7$152
Dendreon Pharmaceuticals LLC4$149
Pharmaessentia USA Corporation6$134
Boehringer Ingelheim5$129
Celltrion USA Inc.1$119
Mirati Therapeutics, Inc.5$116
Servier Pharmaceuticals LLC5$111
Pharmacyclics LLC, An Abbvie Company6$103
Jazz Pharmaceuticals Inc.5$99
Sanofi-aventis U.S. LLC1$98
Deciphera Pharmaceuticals Inc.4$97
Sobi, Inc4$95
Sumitomo Pharma America, Inc.4$92
Beone Medicines USA, Inc.6$89
Myovant Sciences Inc.5$89
AVEO Pharmaceuticals, Inc.4$76
Coherus Oncology, Inc.3$74
Tersera Therapeutics LLC4$69
Geron Corporation3$65
Genmab U.S., Inc.2$63
Pharmacosmos Therapeutics Inc.3$61
Epizyme, Inc.3$51
Exelixis Inc.2$48
ADC Therapeutics America, Inc.3$44
Heron Therapeutics, Inc.2$43
Immunocore Limited2$43
Taiho Oncology, Inc.2$39
EMD Serono, Inc.2$37
Caris MPI, Inc.2$37
Stemline Therapeutics Inc.2$34
Clovis Oncology, Inc.2$33
Novocure Inc.2$30
Recordati_rare_diseases_inc.1$25
Biocon Biologics Inc1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,233 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,134
Medicare patients
91
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane60$10,024
EliquisApixaban12$6,787
Anastrozole83$2,184
Megestrol Acetate17$875
Gabapentin57$758
Letrozole29$756
Ondansetron Hcl30$748
Hydroxyurea18$360
Pantoprazole Sodium27$355
Levothyroxine Sodium39$341
Warfarin Sodium37$254
Tamoxifen Citrate19$241
Escitalopram Oxalate23$102
Paroxetine Hcl12$73
Prednisone20$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,379$6,78712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →